• Neurological Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PND87 SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUES (HSUVS) IN MULTIPLE SCLEROSIS

    Nov 1, 2019, 00:00

  • TP3 CHARACTERIZING AND COMPARING US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY RECEIPT OF MEDICATION-ASSISTED TREATMENT (MAT)

    Nov 1, 2019, 00:00

  • PCN490 MAKING OUTCOME-BASED PAYMENT A REALITY IN THE NATIONAL HEALTH SERVICE FOR ENGLAND

    Nov 1, 2019, 00:00

  • PCN505 COSTS AND TREATMENT PATHWAYS OF OVARIAN CANCER CARE IN KAZAKHSTAN: RETROSPECTIVE ANALYSIS OF PATIENT-LEVEL ELECTRONIC HEALTH RECORDS

    Nov 1, 2019, 00:00

  • PDB91 AN MCDA APPROACH IN THE EVALUATION OF NEW TECHNOLOGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT

    Nov 1, 2019, 00:00

  • PRS39 THE ECONOMIC BURDEN OF ASTHMA

    Nov 1, 2019, 00:00

  • RE4 IS MARKET ACCESS FOR ONCOLOGY TREATMENTS EASIER IN ENGLAND THAN FOR NON-ONCOLOGY TREATMENTS? AN ANALYSIS OF NICE SINGLE TECHNOLOGY APPRAISALS FROM 2017-2019

    Nov 1, 2019, 00:00

  • PMS22 ANNUAL COST OF PATIENTS UNDERGOING A TOTAL KNEE REPLACEMENT IN FRANCE

    Nov 1, 2019, 00:00

  • NO Specific Disease - Organizational Practices

    Nov 1, 2019, 00:00

  • PND114 REAL WORLD PATIENT SURVEY ON HOW MIGRAINE AFFECTS EGYPTIAN SOCIAL AND WORK LIFE

    Nov 1, 2019, 00:00

  • PNS52 ASSESSMENT OF THE IMPACT OF THE LEVEL OF ASMR ON THE DRUG'S PRICE AND ITS NEGOTIATION TIME WITH THE HEALTH AUTHORITIES IN TREATMENTS THAT BENEFITED FROM THE FRENCH EARLY ACCESS PROGRAM

    Nov 1, 2019, 00:00

  • PCN382 TRASTUZUMAB IN THE TREATMENT OF HER2-POSITIVE EARLY ANDLOCALLY ADVANCED BREAST CANCER: THE FIRST HTA REPORT OF INEAS-TUNISIA

    Nov 1, 2019, 00:00

  • NO Specific Disease - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN345 A REVIEW OF DIFFERENCES IN DECISION-MAKING ACROSS NICE HEALTH TECHNOLOGY ASSESSMENTS OF NIVOLUMAB

    Nov 1, 2019, 00:00

  • PCN377 WHERE DO WE GO WITH WHOLE GENOME SEQUENCING IN ONCOLOGY? USING SCENARIO DRAFTING TO EXPLORE FUTURE DEVELOPMENTS

    Nov 1, 2019, 00:00

  • PNS355 HOW INVOLVED SHOULD PAYERS BE IN THE DEVELOPMENTS OF TARGET PRODUCT PROFILE (TPP), PRODUCT DEVELOPMENT PLAN (PDP) AND DESIGN OF CLINICAL TRIALS (DOCT)

    Nov 1, 2019, 00:00

  • PCN456 REAL WORLD HEALTH RELATED QUALITY OF LIFE (HRQOL) FOR FIRST LINE RECURRENT/ METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) PATIENTS

    Nov 1, 2019, 00:00

  • Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England

    Nov 1, 2019, 00:00

  • PCN25 IMPACT OF GEMTUZUMAB OZOGAMICIN ON THE IRISH HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PCN288 HOW IS METASTATIC MELANOMA TREATED IN THE PUBLIC HEALTH SYSTEM IN BRAZIL?: A CALL FOR CHANGE

    Nov 1, 2019, 00:00

  • PMU107 INSIGHTS INTO REIMBURSEMENT RATES AND TIMELINES FOR ORPHAN DRUGS IN IRELAND

    Nov 1, 2019, 00:00

  • PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS

    Nov 1, 2019, 00:00

  • PDG38 RELATIONSHIP BETWEEN RELIGIOSITY-SPIRITUALITY AND MEDICATION ADHERENCE AMONG PATIENTS WITH CARDIOVASCULAR DISEASES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PDB59 EVALUATING THE COST-UTILITY OF ADDING SODIUM-GLUCOSE COTRANSPORTER INHIBITORS TO A BASAL-BOLUS INSULIN REGIMEN IN PATIENTS WITH TYPE 1 DIABETES IN THE UK: AN ANALYSIS USING THE PRIME DIABETES MODEL

    Nov 1, 2019, 00:00

  • PRO25 COST OF HEALTHCARE RESOURCE UTILIZATION IN INTERSTITIAL LUNG DISEASES IN GERMANY IN 2017

    Nov 1, 2019, 00:00

  • PCV53 COST-EFFECTIVENESS OF THE CNIC POLYPILL - FIXED DOSE COMBINATION OF ACETYLSALICYLIC ACID, RAMIPRIL AND ATORVASTATIN - FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE

    Nov 1, 2019, 00:00

  • PMD44 PRICING AND REIMBURSEMENT, AND MARKET ACCESS OF THERAPEUTIC MATERIALS (MEDICAL DEVICES/DIAGNOSTICS/BIOMARKERS) IN SOUTH KOREA.

    Nov 1, 2019, 00:00

  • PNS306 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF RANDOMIZED CONTROLLED TRIALS

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN374 BETTER LATE THAN NEVER: THE DYNAMICS OF NICE DECISION-MAKING UNDER THE NEW MODEL OF THE CDF

    Nov 1, 2019, 00:00

  • PDB2 USING REAL WORLD DATA TO EXAMINE TRIGLYCERIDES, LDL-CHOLESTEROL, AND HDL-CHOLESTEROL AS PREDICTORS OF PROGRESSION FROM NONALCOHOLIC STEATOHEPATITIS TO HEPATOCELLULAR CANCER AND LIVER CIRRHOSIS

    Nov 1, 2019, 00:00

  • PND63 ASSOCIATION BETWEEN TYPE OF SURGERY AND DEVELOPMENT OF PARKINSON'S DISEASE: A NESTED CASE-CONTROL STUDY USING A US INSURANCE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • ON7 TIME-TO-TREATMENT DISCONTINUATION (TTD) AS A PRAGMATIC PREDICTOR OF OVERALL SURVIVAL (OS) IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) - REAL-WORLD PERSPECTIVE

    Nov 1, 2019, 00:00

  • Stated Preference Patient Satisfaction Research

    Nov 1, 2019, 00:00

  • PMH33 COST-UTILITY OF LURASIDONE VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH SCHIZOPHRENIA IN ITALY

    Nov 1, 2019, 00:00

  • PCN484 SYSTEMATIC REVIEW OF A DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURE IN PATIENTS WITH MULTIPLE MYELOMA: EORTC QLQ-MY20 INSTRUMENT DEVELOPMENT AND VALIDATION

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PBI74 MARKET ACCESS LANDSCAPE FOR BIOSIMILARS IN SWEDEN: AN UNTAPPED POTENTIAL?

    Nov 1, 2019, 00:00

  • PND81 LANDSCAPE ASSESSMENT AND KEY HTA CONSIDERATIONS IN ALZHEIMER'S DISEASE

    Nov 1, 2019, 00:00

  • PPM4 COMPREHENSIVE GENOMIC PROFILING FOR NON-SMALL CELL LUNG CANCER (NSCLC): A HEALTH AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PMD42 THE DIRECT COSTS ASSOCIATED WITH POSTERIOR CAPSULE OPACIFICATION IN THE NETHERLANDS: A PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU118 USE OF COMPUTER-ASSISTED METHODS TO REALIZE THE CONCEPT OF A LIVING SYSTEMATIC REVIEW VIA AN ONLINE PLATFORM

    Nov 1, 2019, 00:00

  • PNS269 PERSPECTIVES ON PRICING AND REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE GREEK HEALTHCARE SETTING: A QUALITATIVE STUDY

    Nov 1, 2019, 00:00

  • Mental Health - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PDG52 CONSISTENCY OF NEW DRUG PRICING IN KOREA: BRIDGING VARIATIONS AMONG PERSONNEL IN PRICE NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PNS394 DEVELOPMENT OF A MULTIPLICATIVE MULTI-ATTRIBUTE AND SINGLE-ATTRIBUTE UTILITY FUNCTION FOR THE HUI3 IN JAPAN

    Nov 1, 2019, 00:00

  • PNS158 HEALTH ECONOMIC VALUE OF BLOOD IN SUB-SAHARAN AFRICA: THE CASE OF MATERNAL BLEEDING

    Nov 1, 2019, 00:00

  • PCN5 REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE

    Nov 1, 2019, 00:00

  • Neurological Disorders Studies

    Nov 1, 2019, 00:00

  • PMS55 TREATMENT PATTERNS AMONG MS PATIENTS NEWLY INITIATING DISEASE-MODIFYING THERAPY

    Nov 1, 2019, 00:00

  • PRS17 COST-EFFECTIVENESS OF A HYPOTHETICAL SCREENING PROGRAM FOR LUNG CANCER AND CARDIOVASCULAR DISEASE IN CHINA

    Nov 1, 2019, 00:00

  • PIH18 PREDICTED COST AND CAPACITY BENEFITS OF THE DIGITALIZED SECONDARY CARE PATH FOR WOMEN WITH ENDOMETRIOSIS @ VIRTUAL HOSPITAL 2.0

    Nov 1, 2019, 00:00

  • PNS216 NICE HIGHLY SPECIALISED TECHNOLOGY ASSESSMENT: HOW ARE SELECTION CRITERIA APPLIED IN PRACTICE?

    Nov 1, 2019, 00:00

  • PRS30 PRAGMATIC META-ANALYSIS OF PROPORTIONAL ASSIST VENTILATION+ VERSUS PRESSURE SUPPORT VENTILATION AND ITS IMPACT ON COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • PCN279 EFFECT OF THE CHANGE IN COST-EFFECTIVENESS THRESHOLD ON THE NEWLY LISTED ANTICANCER DRUG PRICES IN THE NATIONAL HEALTH INSURANCE OF SOUTH KOREA

    Nov 1, 2019, 00:00

  • PRS23 COST-EFFECTIVENESS OF TIOTROPIUM + OLODATEROL VERSUS ACLIDINIUM + FORMOTEROL FIXED-DOSE COMBINATIONS IN THE MANAGEMENT OF MODERATE-TO-SEVERE COPD IN IRAN

    Nov 1, 2019, 00:00

  • HT2 IS THERE POTENTIAL FOR JOINT HEALTH TECHNOLOGY ASSESSMENT (HTA) IN EUROPE? AN EVALUATION OF EUNETHTA JOINT CLINICAL ASSESSMENTS VS. NATIONAL APPRAISALS IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PMH24 DEPENDENCE AS A MEASURE OF HEALTH BENEFIT IN THE ECONOMIC EVALUATION OF DEMENTIA INTERVENTIONS

    Nov 1, 2019, 00:00

  • PMH38 IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH HYPONATREMIA IN PSYCHIATRIC PATIENTS: A CASE CONTROL STUDY

    Nov 1, 2019, 00:00

  • PNS308 METHODOLOGICAL APPROACHES FOR INCORPORATING INVESTIGATORS' CHOICE COMPARATOR ARMS INTO NETWORK META-ANALYSES

    Nov 1, 2019, 00:00

  • PMH60 ASSESSMENT OF THE INTERNAL CONSISTENCY AND CONCURRENT VALIDITY OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN AN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER POPULATION-BASED SAMPLE

    Nov 1, 2019, 00:00

  • PNS183 UNIVERSAL HEALTH INSURANCE COVERAGE FOR CHILDREN UNDER AGE 6: FACTORS ASSOCIATED WITH THE USE OF PRIVATE OVER PUBLIC HEALTH SERVICES IN VIETNAM

    Nov 1, 2019, 00:00

  • PSU17 ECONOMIC ANALYSIS OF SUGAMMADEX FOR REVERSAL OF NEUROMUSCULAR BLOCKADE IN LAPAROSCOPIC SURGERY IN CHINA

    Nov 1, 2019, 00:00

  • RARE Statistical Research

    Nov 1, 2019, 00:00

  • PCN291 ADEQUATE DATA SOURCES TO FACILITATE INNOVATIVE PRICING SOLUTIONS FOR PHARMACEUTICALS WITH MULTIPLE INDICATIONS IN GERMANY

    Nov 1, 2019, 00:00

  • SP3 PATIENTS' PREFERENCES FOR BREAST CANCER TREATMENTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY FROM SPAIN, FRANCE, POLAND AND IRELAND

    Nov 1, 2019, 00:00

  • PCN501 VALUE FOR MONEY IN METASTATIC CUTANEOUS MELANOMA: DO BENEFITS OUTWEIGH THE COSTS OF NOVEL DRUGS?

    Nov 1, 2019, 00:00

  • PRS31 THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN

    Nov 1, 2019, 00:00

  • MT2 UNDERSTANDING POTENTIAL CAPACITY CONSTRAINTS RESTRICTING TIME-TO-DIAGNOSIS IN A MULTI-DISCIPLINARY DIAGNOSTIC CENTRE (MDC) FOR PEOPLE WITH NON-SPECIFIC SYMPTOMS OF CANCER: A DISCRETE EVENT SIMULATION

    Nov 1, 2019, 00:00

  • PDG29 ORPHAN DRUGS ASSESMENT IN FRANCE: ACCEPTABILITY OF THE CLINICAL DATA FOR THE ECONOMIC EVALUATION

    Nov 1, 2019, 00:00

  • PRO133 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND PULMONARY ARTERIAL HYPERTENSION (PAH) DISEASE SEVERITY: A REVIEW OF GRIPHON, SERAPHIN, COMPASS-2 AND EARLY TRIALS

    Nov 1, 2019, 00:00

  • PMU37 NEWLY DIAGNOSED NONALCOHOLIC FATTY LIVER DISEASE AFTER BARIATRIC SURGERY: A STUDY OF ELECTRONIC MEDICAL RECORD DATA

    Nov 1, 2019, 00:00

  • PSY12 COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN315 USE OF NOVEL HORMONAL AGENTS IN THE MONTH BEFORE DYING IN MEN DYING OF PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PNS72 EVALUATION OF MEDICAL TECHNOLOGIES WITH UNCERTAIN BENEFITS

    Nov 1, 2019, 00:00

  • PMH58 COMPARATIVE ANALYSIS BETWEEN THE MICROSTRUCTURE NETWORK MANAGEMENT AND THE CONVENTIONAL MEDICAL OF PERSONS WITH ADDICTION IN FRANCE

    Nov 1, 2019, 00:00

  • PCN161 COST-EFFECTIVENESS OF FOLFIRI + CETUXIMAB VS. FOLFIRI + BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 ...

    Nov 1, 2019, 00:00

  • PCN202 LIQUID BIOPSY FOR EGFR+ PATIENTS IN ADVANCED NSCLC: THE IMPACT OF DIFFERENT STRATEGIES

    Nov 1, 2019, 00:00

  • PNS377 BARRIERS AND ENABLERS TO PATIENT ENGAGEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS: AN IRISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PBI35 HEALTH ECONOMICS MODELLING FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP): A TARGETED LITERATURE REVIEW (LR)

    Nov 1, 2019, 00:00

  • PRO131 WHAT DO WE KNOW ABOUT PATIENT'S AND CAREGIVERS' EXPERIENCE WHEN LIVING WITH THE HEREDITARY RETINAL CONDITION RETINITIS PIGMENTOSA?

    Nov 1, 2019, 00:00

  • PCV84 REHOSPITALIZATION DUE TO SUBSEQUENT CARDIOVASCULAR EVENTS IN SECONDARY PREVENTION PATIENTS TREATED WITH LIPID LOWERING THERAPIES IN ITALY

    Nov 1, 2019, 00:00

  • Mental Health - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS238 THE CHANGING DYNAMICS OF PATIENT ACCESS SCHEMES IN ENGLAND

    Nov 1, 2019, 00:00

  • PGI2 EVALUATION OF PATIENTS DEPRESCRIBED OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS USING KWAS QUESTIONNAIRE

    Nov 1, 2019, 00:00

  • PSU7 THE DUTCH REFERENCE PRICE FOR INPATIENT DAYS SHOULD BE USED WITH SOME CAUTION

    Nov 1, 2019, 00:00

  • PNS328 REAL OPTIONS ANALYSIS FOR MORE OPTIMALLY INFORMED REIMBURSEMENT DECISIONS

    Nov 1, 2019, 00:00

  • PCN295 THE BEHAVIOUR OF THE CANCER DRUGS FUND (CDF) OVER TIME; THE IMPACT OF INNOVATIVE THERAPIES AND IMPLICATIONS FOR MANAGED ENTRY AGREEMENTS

    Nov 1, 2019, 00:00

  • PMU49 NEGOTIATION OUTCOMES IN ITALY: WHAT’S THE IMPACT OF ORPHAN DRUG DESIGNATION?

    Nov 1, 2019, 00:00

  • PNS327 DO FLEXIBLE SURVIVAL MODELS PROVIDE BETTER EXTRAPOLATIONS THAN STANDARD SURVIVAL MODELS? A SIMULATION STUDY

    Nov 1, 2019, 00:00

  • Medical Devices - Economic Evaluation

    Nov 1, 2019, 00:00

  • PIN32 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF VACCINATING ADULTS AGAINST PNEUMOCOCCAL-DISEASES IN AUSTRIA

    Nov 1, 2019, 00:00

  • PCV58 TOTAL COSTS OF TREATMENT OF PATIENTS SUFFERING FROM VENOUS THROMBOEMBOLISM - IMPLICATIONS OF DIFFERENT COST PERSPECTIVES

    Nov 1, 2019, 00:00

  • PAM14 ASSESSING THE NUTRITIONAL STATUS OF THE ELDERLY USING STANDARD STATUS SCALES

    Nov 1, 2019, 00:00

  • PMH23 A RETROSPECTIVE CHART REVIEW STUDY TO QUANTIFY THE MONTHLY MEDICAL RESOURCE USE AND COSTS OF TREATING PATIENTS WITH TREATMENT RESISTANT DEPRESSION IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PMU149 DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CANCER PATIENTS: DID THEY INCREASE IN RECENT YEARS?

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMU5 ASSESSMENT OF ADVERSE DRUG REACTIONS IN PATIENTS WITH HEPATIC DISEASES AT THE DEPARTMENT OF GASTROENTEROLOGY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PND70 NARCOLEPSY TREATMENT IN SWEDEN: REGISTER BASED STUDY

    Nov 1, 2019, 00:00

  • PRS24 COST EFFECTIVENESS OF BENRALIZUMAB FOR SEVERE, UNCONTROLLED ORAL CORTICOSTEROID-DEPENDENT ASTHMA IN SWEDEDN

    Nov 1, 2019, 00:00

  • PBI57 PAYER AND PHYSICIAN DYNAMICS SURROUNDING BIOSIMILAR ACCESS IN THE EU

    Nov 1, 2019, 00:00

  • PDB42 COST-EFFECTIVENESS ANALYSIS FOR HBA1C TEST INTERVALS IN PATIENTS ON TREATMENT FOR STABLE TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PNS246 EMA G-BA - A COMPARISON OF TIME LIMITATIONS OF EUROPEAN MARKETING AUTHORIZATIONS AND GERMAN ADDED BENEFIT ASSESSMENTS FOR NEW PHARMACEUTICALS.

    Nov 1, 2019, 00:00

  • PNS243 TRENDS IN DECISIONS BY THE SCOTTISH MEDICINES CONSORTIUM OVER THE PAST 10 YEARS - AN ANALYSIS OF KEY FACTORS DRIVING ACCEPTANCE

    Nov 1, 2019, 00:00

  • PCN69 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT TARGET DRUGS FOR SECOND-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PCV80 EVALUATION OF THE QUALITY OF LIFE OF PATIENTS WITH CARDIOVASCULAR DISEASES IN NUR-SULTAN, KAZAKHSTAN

    Nov 1, 2019, 00:00

  • PNS248 DOES THE EVALUATION OF THE FRENCH TRANSPARENCY COMMITTEE (TC) ON DRUG EFFECTIVENESS HAVE AN IMPACT ON THE HEALTH-ECONOMIC EVALUATION CONDUCTED BY THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP)?

    Nov 1, 2019, 00:00

  • PNS267 MODELLING OF LIFECYCLE PRICING IN HTA: METHODOLOGICAL CONSIDERATIONS

    Nov 1, 2019, 00:00

  • PIN108 THE BURDEN OF EBOLA VIRUS DISEASE (EVD) IN AFRICA: NEED FOR VACCINE (A TARGETED LITERATURE REVIEW)

    Nov 1, 2019, 00:00

  • PND38 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO ERENUMAB AS PREVENTIVE TREATMENT IN EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PND73 FACTORS INFLUENCING INTENTION TO ENGAGE IN PREVENTIVE BEHAVIORS FOR ALZHEIMER'S DISEASE: A PROTECTION MOTIVATION THEORY APPROACH

    Nov 1, 2019, 00:00

  • PRO121 THE USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT OF MEDICATIONS FOR RARE DISEASES

    Nov 1, 2019, 00:00

  • PCN240 POTENTIAL BUDGET IMPACT OF ADJUVANT TREATMENTS FOR STAGE III MELANOMA IN IRELAND

    Nov 1, 2019, 00:00

  • PMU132 PUBLICATION PATTERNS IN PATIENT-REPORTED OUTCOMES IN ORIGINAL RESEARCH ARTICLES ABOUT DIABETES AND INFLAMMATORY BOWEL DISEASE

    Nov 1, 2019, 00:00

  • PCN528 ASSOCIATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH LUNG CANCER AMONG A U.S. COHORT: A REAL WORLD APPROACH

    Nov 1, 2019, 00:00

  • PSU41 COMPLIANCE WITH SURGICAL ANTIBIOTIC PROPHYLAXIS FOR OBSTETRIC AND GYNECOLOGIC SURGERIES IN NIGERIA: A RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PGI6 TREATMENT FAILURE AND REMISSION IN MODERATE TO SEVERE ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD) IN EUROPE

    Nov 1, 2019, 00:00

  • PRO50 THE ECONOMIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PMU97 A REVIEW OF CONTRIBUTIONS MADE BY PATIENT ADVOCACY GROUPS IN THE ASSESSMENT OF DRUGS BY THE FRENCH HAUTE AUTORITE DE SANTE

    Nov 1, 2019, 00:00

  • PND92 TREATMENT PATTERNS AND CHARACTERIZATION OF MIGRAINE PATIENTS FOLLOWED IN HEADACHE SPECIALIZED CENTERS OF PORTUGAL

    Nov 1, 2019, 00:00

  • PCN209 END-OF-LIFE COST FOR LUNG CANCER PATIENTS IN GREECE: A HOSPITAL-BASED RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PNS298 PER-MEMBER PER-MONTH (PMPM) EXPENDITURE VALUE IN ONCOLOGY: A QUICK LITERATURE REVIEW AND OPINION

    Nov 1, 2019, 00:00

  • PND52 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Nov 1, 2019, 00:00

  • PMU9 HIGH DRUG PRICES AND THE ADEQUACY OF RETURN ON PUBLIC INVESTMENT INTO DRUG RESEARCH AND DEVELOPMENT BY THE U.S. NATIONAL INSTITUTES OF HEALTH (NIH).

    Nov 1, 2019, 00:00

  • PCN387 ARE NICE APPRAISAL COMMITTEES BEING CONSISTENT IN THEIR IMPLEMENTATION OF THE END OF LIFE CRITERION?

    Nov 1, 2019, 00:00

  • PRO109 A COMPARATIVE REVIEW OF NICE AND SMC DECISION-MAKING FOR ULTRA-ORPHAN MEDICINES

    Nov 1, 2019, 00:00

  • NO Specific Disease - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN363 IMPACT OF OUTCOMES ON IQWIGS OVERALL BENEFIT RATING

    Nov 1, 2019, 00:00

  • PNS146 WHAT APPROACH SHOULD BE TAKEN IN ORDER TO EFFECTIVELY MANAGE BEHAVIORAL HEALTH RISK FACTORS? A CONSENSUS PANEL ANALYSIS FOR GREECE

    Nov 1, 2019, 00:00

  • PNS19 THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE'S HIGHLY SPECIALISED TECHNOLOGIES PROCESS: A REVIEW OF PAST SUBMISSIONS AND RECOMMENDATIONS FOR THE FUTURE

    Nov 1, 2019, 00:00

  • PRS29 COMPARATIVE PHARMACOECONOMICS OF BX IN THE TREATMENT OF PATIENTS WITH UNCONTROLLED MODERATE AND SEVERE ATOPIC ASTHMA IN THE RUSSIAN HEALTH CARE SETTING

    Nov 1, 2019, 00:00

  • PNS8 IDENTIFYING MECHANISMS IN PARTICIPANT RECRUITMENT IN THE DANSIH EQ-5D-5L VALUATION STUDY

    Nov 1, 2019, 00:00

  • PMS69 EFFECT OF HIP FLEXION CONTRACTURE ON TERMINAL STANCE OF GAIT AMONG INACTIVE UNIVERSITY STUDENTS

    Nov 1, 2019, 00:00

  • PIN135 MODELING HUMAN PAPILLOMAVIRUS TRANSMISSION FOR VACCINE EVALUATIONS: A PRELIMINARY AGENT-BASED MODEL

    Nov 1, 2019, 00:00

  • PRS15 COMPARISON OF HOSPITALIZATION RATES AND LIMITATION OF DAILY ACTIVITIES IN SEVERE ASTHMA PATIENTS RECEIVING BIOLOGIC AND NON-BIOLOGIC TREATMENT REGIMENS

    Nov 1, 2019, 00:00

  • PNS82 HOW TO DEAL WITH CONTRADICTORY COST-EFFECTIVENESS OF THERAPEUTICALLY SIMILAR MEDICINES?

    Nov 1, 2019, 00:00

  • Alternative Medicine Process of Care

    Nov 1, 2019, 00:00

  • PGI18 ASSESSMENT OF MEDICAL COSTS ASSOCIATED WITH CROHN'S DISEASE: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDB111 EMPAGLIFLOZIN INDUCED PANCREATITIS: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PMH50 THE LONGITUDINAL VALIDITY OF THE CHU9D - EVIDENCE FROM A MENTAL HEALTH TRIAL

    Nov 1, 2019, 00:00

  • PCV30 COST-EFFECTIVENESS OF NOACS IN PATIENTS WITH ATRIAL FIBRILLATION: USING REAL-WORLD DATA FOR EXTERNAL VALIDATION

    Nov 1, 2019, 00:00

  • PCV60 BURDEN OF CARDIOVASCULAR DISEASE AND POTENTIAL IMPACT OF PCSK9I IN THE PREVENTION OF CARDIOVASCULAR EVENTS IN SWITZERLAND

    Nov 1, 2019, 00:00

  • NO Specific Disease - Medical Technologies

    Nov 1, 2019, 00:00

  • PND78 MULTIPLE SCLEROSIS IN PUERTO RICO: AN ANALYSIS OF DEMOGRAPHICS AND TREATMENT MODALITIES BY GEOGRAPHICAL REGION

    Nov 1, 2019, 00:00

  • PCN346 MEAN VERSUS MEDIAN: WHAT DOES NICE CONSIDER TO BE THE MOST APPROPRIATE STATISTIC FOR ESTIMATING SHORT LIFE EXPECTANCY TO SATISFY END-OF-LIFE CRITERIA?

    Nov 1, 2019, 00:00

  • Injury Trauma - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS135 ARE THE SALES FORECAST FOR MEDICAL DEVICES ACCURATE? A RETROSPECTIVE ANALYSIS IN FRANCE (2018-2019)

    Nov 1, 2019, 00:00

  • PRO8 EFFICACY OF CFTR MODULATORS AGAINST PULMONARY EXACERBATION IN CYSTIC FIBROSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PAM12 GENDER DIFFERENCES IN THE DIETARY HABITS OF SECONDARY SCHOOL STUDENTS

    Nov 1, 2019, 00:00

  • PCN333 PREFERENCE ELICITATION FOR CANCER TREATMENT IN EUROPE: A SYSTEMATIC LITERATURE REVIEW OF DISCRETE CHOICE EXPERIMENTS

    Nov 1, 2019, 00:00

  • PDG73 INCLUSION OF ADVERSE EVENTS IN THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: A REVIEW OF THE MANUFACTURERS' SUBMISSIONS TO THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)

    Nov 1, 2019, 00:00

  • PRO160 COST ESTIMATION OF IMMUNOGLOBULIN RESCUE IN HOSPITALIZED PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): ANALYSIS OF A BRAZILIAN PRIVATE HEALTHCARE SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PSU4 COMPARISON OF OBESITY CLASSIFICATIONS AT 1, 3, AND 5 YEARS AFTER GASTRIC BYPASS AND GASTRIC SLEEVE SURGERY USING A FEDERATED ELECTRONIC MEDICAL RECORD (EMR) NETWORK

    Nov 1, 2019, 00:00

  • PCN104 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES OF CANCER IMMUNOTHERAPY MEDICINES

    Nov 1, 2019, 00:00

  • Drugs Statistical Research

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN125 IMPACT OF PALLIATIVE CARE CONSULT SERVICES ON THE COST OF CARE IN HUNGARY

    Nov 1, 2019, 00:00

  • PDG49 THE IMPACT OF FUTURE MEDICAL COSTS ON DUTCH PHARMACOECONOMIC ASSESSMENTS

    Nov 1, 2019, 00:00

  • PIT9 IMPACT OF FALLS IN THE ELDERLY POPULATION FOR THE SPANISH NATIONAL HEALTH SYSTEM

    Nov 1, 2019, 00:00

  • PNS294 REVIEW OF ANALYTICAL METHODS FOR ANALYSIS OF PATIENT REPORTED OUTCOME (PRO) DATA IN THE PRESENCE OF CENSORING DUE TO DEATH

    Nov 1, 2019, 00:00

  • PMS68 PREDICTORS OF AGREEMENT BETWEEN PATIENT AND CLINICIAN GLOBAL ASSESSMENTS OF RHEUMATOID ARTHRITIS SEVERITY

    Nov 1, 2019, 00:00

  • PNS4 A REVIEW OF PERFOS IN FDA AND EMA LABELLING CLAIMS (2009-2019)

    Nov 1, 2019, 00:00

  • PNS357 HOW TO RESOLVE ISSUES EXPERIENCED BY PAYERS FOR THEIR INVOLVEMENT AT PRE-LAUNCH STAGE

    Nov 1, 2019, 00:00

  • PCN262 ESTIMATION OF THE NUMBER OF PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS416 A MODEL-BASED STANDARDISATION APPROACH TO INCREASE GENERALISABILITY OF CLAIMS DATA ANALYSES: THE EXAMPLE OF GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • Injury Trauma - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMH62 IMPROVEMENT IN FUNCTIONING, DEPRESSIVE AND COGNITIVE SYMPTOMS AFTER TREATMENT OF MAJOR DEPRESSION WITH VORTIOXETINE. INTERIM RESULTS FROM THE "REAL-LIFE EFFECTIVENESS OF VORTIOXETINE (RELIEVE)” STUDY

    Nov 1, 2019, 00:00

  • PRO142 PSYCHOMETRIC PERFORMANCE OF THE INDOLENT SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ISM-SAF)

    Nov 1, 2019, 00:00

  • PNS233 ECONOMIC MODEL AND METHODOLOGIES EMPLOYED IN RECENT NICE SINGLE TECHNOLOGY APPRAISAL SUBMISSIONS

    Nov 1, 2019, 00:00

  • PDG37 REAL-WORLD USE OF SELEXIPAG AND OTHER PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPIES: AN OBSERVATIONAL COHORT STUDY IN PATIENTS WITH PAH (EXPOSURE)

    Nov 1, 2019, 00:00

  • PIN63 COST-EFFECTIVENESS ANALYSIS OF POSACONAZOLE VERSUS VORICONAZOLE FOR THE PROPHYLAXIS OF INVASIVE FUNGAL DISEASE IN CHINA

    Nov 1, 2019, 00:00

  • PCN120 UTILIZATION AND EXPENDITURE OF COLORECTAL CANCER DRUGS IN THE MEDICAID PROGRAM FROM 1996 TO 2017

    Nov 1, 2019, 00:00

  • PCN361 A MULTICRITERIA DECISION ANALYSIS (MCDA) TO EVALUATE ALTERNATIVE MAINTENANCE STRATEGIES FOR TREATMENT OF RECENTLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC) WITH BRCA MUTATION UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN98 COST-COMPARISON ANALYSIS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) AND TRANSARTERIAL CHEMOEMBOLISATION (TACE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • PNS89 CATEGORIZATION AND ASSOCIATION ANALYSIS OF RISK FACTORS FOR SAFE DRUG DISPOSAL

    Nov 1, 2019, 00:00

  • PRO57 COST MINIMIZATION ANALYSIS OF EMICIZUMAB IN THE PROPHYLAXIS OF INHIBITOR-NEGATIVE PATIENTS WITH HEMOPHILIA A IN TURKEY

    Nov 1, 2019, 00:00

  • PMH7 LEVERAGING INNOVATIVE DIGITAL TECHNOLOGY: A NOVEL APPROACH TO SERVICE OPTIMISATION

    Nov 1, 2019, 00:00

  • PCN204 COST-ESTIMATE OF ADDING NEOADJUVANT PERTUZUMAB FOR THE TREATMENT OF HER2+ BREAST CANCER IN AN INSTITUTION IN PORTUGAL

    Nov 1, 2019, 00:00

  • PND104 DIAGNOSIS AND TREATMENT PATTERNS ON BRAZILIAN PATIENTS: RESULTS FROM THE MY MIGRAINE VOICE SURVEY

    Nov 1, 2019, 00:00

  • PCN319 CONTEMPORARY EVIDENCE ON GLOBAL ECONOMIC BURDEN OF FRONTLINE CARE FOR PERIPHERAL T-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PIN39 WHEN A PROBIOTIC-BASED SANITIZING METHOD MAY HALVE HEALTHCARE-ASSOCIATED INFECTIONS AND REDUCE ASSOCIATED COSTS

    Nov 1, 2019, 00:00

  • PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA)

    Nov 1, 2019, 00:00

  • PCN61 A FREELY AVAILABLE GENERIC COST-EFFECTIVENESS MODEL IN ONCOLOGY FOR EARLY-STAGE DECISION MAKING

    Nov 1, 2019, 00:00

  • PCN133 A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN OF NEWLY DIAGNOSED MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PNS335 USING MACHINE LEARNING FOR EFFICIENCY IMPROVEMENTS IN SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EFFICACY AND SAFETY

    Nov 1, 2019, 00:00

  • PBI40 TENDER APPROACHES IN THE OFF-PATENT BIOLOGICAL MEDICINES MARKET: A EUROPEAN COMPARATIVE ANALYSIS

    Nov 1, 2019, 00:00

  • PRO58 CLINICAL AND ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN FRANCE: A RETROSPECTIVE ANALYSIS OF THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Nov 1, 2019, 00:00

  • PNS17 ASSESSING TECHNOLOGIES THAT ARE EFFECTIVE BUT NOT COST-EFFECTIVE AT ZERO PRICE: AN ALTERNATIVE FRAMEWORK

    Nov 1, 2019, 00:00

  • PDG6 A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS (NMA) OF CRISABOROLE 2% OINTMENT FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS (AD)

    Nov 1, 2019, 00:00

  • PND40 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

    Nov 1, 2019, 00:00

  • PMU135 PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH CHRONIC OCULAR SURFACE PAIN : A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDG30 PHARMACOECONOMIC EVALUATION OF ANTI-VEGF DRUGS AND LASER PHOTOCOAGULATION FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN CHINA

    Nov 1, 2019, 00:00

  • PIN84 KNOWLEDGE, ATTITUDE AND PRACTICES ABOUT ZIKA VIRUS AMONG PHARMACY STUDENTS IN MAINLAND UNITED STATES (US) AND NON-MAINLAND US (PUERTO RICO AND WEST INDIES

    Nov 1, 2019, 00:00

  • PMS53 THE MOST COMMON REASONS FOR A MEDICAL VISIT AMONG PEOPLE PERFORMING CONDITIONING GYM WEIGHT TRAINING

    Nov 1, 2019, 00:00

  • PIH15 EXTERNAL VALIDATION OF THE EX-ANTE BUDGET IMPACT ANALYSIS FOR PALIVIZUMAB

    Nov 1, 2019, 00:00

  • NO Specific Disease - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PNS313 A SYSTEMATIC REVIEW OF PATIENT EXPERIENCE DATA CAPTURED IN CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PDB48 COST AND CAPACITY EFFECTS OF HEALTHYWEIGHTHUB @ VIRTUAL HOSPITAL 2.0 IN FINLAND

    Nov 1, 2019, 00:00

  • PDB8 COMPARATIVE EFFECTIVENESS OF LIRAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN: A POPULATION-BASED COHORT STUDY

    Nov 1, 2019, 00:00

  • PCN73 ECONOMIC EVALUATION OF TARGETED TREATMENTS FOR BRAFV600 POSITIVE MELANOMA IN THE IRISH HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • PCN316 TREATMENT PATTERNS OF ADVANCED SOFT-TISSUE SARCOMA IN ARGENTINA

    Nov 1, 2019, 00:00

  • PIH16 THE COST-EFFECTIVENESS OF STRATEGIES PREVENTING LATE-ONSET INFECTION IN PRETERM INFANTS

    Nov 1, 2019, 00:00

  • PRO43 BURDEN OF ILLNESS AMONG PATIENTS WITH HEREDITARY TRANSTHYRETIN (HATTR) AMYLOIDOSIS

    Nov 1, 2019, 00:00

  • PIN19 ECONOMIC EVALUATION OF THE FIRST PILOT OF PARTIAL DECENTRALIZATION OF HIV CARE AND TREATMENT FOR MEN WHO HAVE SEX WITH MEN IN GUATEMALA CITY FROM THE PATIENT'S PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN321 IMAGING SURVEILLANCE OF PATIENTS WITH OVARIAN CANCER AFTER SUCCEEDING EARLY TREATMENT: A CROSS-SECTIONAL ANALYSIS FROM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PRO77 INTERNATIONAL VARIATIONS IN THE APPRAISAL OF DRUGS FOR RARE DISEASES; WHAT ARE THE MAIN LESSONS?

    Nov 1, 2019, 00:00

  • PDB101 PATTERNS OF ADHERENCE, PERSISTENCE, AND SWITCHING AMONG AUSTRALIANS PRESCRIBED DIPEPTIDYL PEPTIDASE-4 INHIBITORS

    Nov 1, 2019, 00:00

  • PCN498 REAL-WORLD EVIDENCE ON THE UTILISATION OF ABIRATERONE AND ENZALUTAMIDE IN IRELAND

    Nov 1, 2019, 00:00

  • PDB130 ECONOMIC BURDEN OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR THERAPIES: ANALYSIS OF NATIONAL SPECIALTY PHARMACY DATABASE

    Nov 1, 2019, 00:00

  • PCV31 PATIENTS' PRODUCTIVITY LOSSES AND INFORMAL CARE COST RELATED TO ISCHEMIC STROKE IN RHONE AREA, FRANCE

    Nov 1, 2019, 00:00

  • PCN156 COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED ITALIAN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA

    Nov 1, 2019, 00:00

  • PNS300 HOW TO INTERPRET AND ACCOUNT FOR OVER/UNDER-DISPERSION WHEN MODELLING INCIDENCE RATES WITH POISSON MODELS

    Nov 1, 2019, 00:00

  • PCN391 RISK-SHARING AGREEMENTS FOR ONCOLOGY DRUGS IN SWEDEN – THE NEW STANDARD FOR ACCESS?

    Nov 1, 2019, 00:00

  • PMS24 HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ELBOW AND FOREARM IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PSU24 COMPARATIVE SAFETY OF SLEEVE GASTRECTOMY VS. ROUX-EN-Y: A RETROSPECTIVE COHORT ANALYSIS

    Nov 1, 2019, 00:00

  • PDG17 HOSPITAL COSTS ASSOCIATED WITH THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE IN HUNGARY

    Nov 1, 2019, 00:00

  • PCV150 DO WEATHER CHANGES AFFECT THE RISK OF STROKE? AN ANALYSIS USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PND105 HEALTHCARE RESOURCE UTILIZATION OF MIGRAINE IN BRAZIL: RESULTS FROM THE MY MIGRAINE VOICE SURVEY

    Nov 1, 2019, 00:00

  • PCN194 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND

    Nov 1, 2019, 00:00

  • PMU63 FRENCH HEALTH TECHNOLOGY ASSESSMENT OF DRUGS APPROVED UNDER EXCEPTIONAL CIRCUMSTANCES

    Nov 1, 2019, 00:00

  • PCN512 PROGRESSION, OVERALL SURVIVAL, AND HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY: A SWEDISH REGISTER-BASED STUDY

    Nov 1, 2019, 00:00

  • PDB13 EVALUATING THE ECONOMIC AND HUMANISTIC BURDEN OF TYPE 2 DIABETES MELLITUS IN EMERGING MARKETS COMPARED TO ESTABLISHED MARKETS

    Nov 1, 2019, 00:00

  • PNS383 HEALTH-RELATED QUALITY OF LIFE IN ROMANIA: CROSS-SECTIONAL STUDIES USING EQ-5D-3L AND EQ-5D-5L

    Nov 1, 2019, 00:00

  • PCN286 HEALTH TECHNOLOGY ASSESSMENT DECISIONS OVER THE LAST DECADE IN THE UNITED KINGDOM AND THE NETHERLANDS - A FOCUS ON NON-SMALL-CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PCN28 METHOD TO ESTIMATE IMPACT OF PROGNOSTIC FACTORS ON SURVIVAL OUTCOMES USING MAXIMUM LIKELIHOOD ESTIMATION

    Nov 1, 2019, 00:00

  • PNS66 NON-INFERIORITY TRIALS IN HEALTH TECHNOLOGY ASSESSMENT - DO THEY NECESSITATE A COST-MINIMISATION APPROACH?

    Nov 1, 2019, 00:00

  • PMU35 QUANTIFYING THE LOST MARKET SIZE OPPORTUNITY OF A TNF-INHIBITOR DUE TO DELAY IN TIME FROM PRIMARY TO SECONDARY INDICATION APPROVAL

    Nov 1, 2019, 00:00

  • PBI52 ATMPS IN EUROPE: EXISTING CHALLENGES AND FUTURE DIRECTIONS

    Nov 1, 2019, 00:00

  • RARE Public Health

    Nov 1, 2019, 00:00

  • PBI34 BUDGET IMPACT OF TRASTUZUMAB BIOSIMILARS FOR THE TREATMENT OF BREAST CANCER AND GASTRIC CANCER IN GREECE

    Nov 1, 2019, 00:00

  • PCN168 ECONOMIC BURDEN OF RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): A RETROSPECTIVE CLAIMS-BASED ANALYSIS

    Nov 1, 2019, 00:00

  • PNS280 AN ASSESSMENT OF THE LIKELIHOOD OF RECEIVING A POSITIVE RECOMMENDATION THROUGH NICE'S STA PROCESS WITHOUT A PATIENT ACCESS SCHEME OF COMMERCIAL ACCESS AGREEMENT

    Nov 1, 2019, 00:00

  • PNS240 POTENTIAL INFLUENCE OF HTA ON PRICE OUTCOMES OF NON-ORPHAN PHARMACEUTICALS IN THE GERMAN AMNOG PROCESS

    Nov 1, 2019, 00:00

  • PRO48 COST OF HAEMATOPOIETIC STEM CELL TRANSPLANT IN TURKEY

    Nov 1, 2019, 00:00

  • PCN404 HOW DO NEW ONCOLOGY VALUE ASSESSMENT FRAMEWORKS COMPARE TO THE QALY?

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN3 RITUXIMAB-BASED REGIMEN AS FRONTLINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD NATIONWIDE COHORT STUDY

    Nov 1, 2019, 00:00

  • PGI52 INTERNATIONAL ADAPTATION AND LINGUISTIC VALIDATION OF NASH-CHECK, A NOVEL PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Economic Evaluation

    Nov 1, 2019, 00:00

  • TP4 USE OF EPISODIC THERAPY IN MODERATE/SEVERE HEMOPHILIA A PATIENTS ACROSS THE EU5

    Nov 1, 2019, 00:00

  • Multiple Diseases - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PRO89 TOO ULTRA-RARE FOR CARE? ORPHAN DRUG AVAILABILITY FOR RESPIRATORY DISEASES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PNS413 DEVELOPMENT, VALIDATION AND CONCORDANCE OF CLINICAL CODE SETS USED IN REAL-WORLD DATABASE STUDIES

    Nov 1, 2019, 00:00

  • PCN300 CERVICAL CANCER PREVENTION IN INDONESIA: AN UPDATED CLINICAL IMPACT, COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PDG53 A FOCUS GROUP STUDY TO IDENTIFY THE FACTORS INFLUENCING PRIORITY SETTING IN HEALTHCARE: FOCUSING ON AGE AND SEVERITY

    Nov 1, 2019, 00:00

  • PMU114 SPECIALISED HEALTH TECHNOLOGY ASSESSMENT PROCESSES FOR VERY RARE DISEASES: PAST, PRESENT AND FUTURE

    Nov 1, 2019, 00:00

  • PND113 DESIGN OF THE INDIVIDUALISED PARKINSON'S DEPENDENT QUALITY OF LIFE (PARKINSON'SDQOL) AND THE PARKINSONS TREATMENT SATISFACTION QUESTIONNAIRE (PARKINSON'STSQ) USING TEMPLATES AND ITEM LIBRARIES FROM EXISTING DQOL AND TSQ MEASURES FOR ...

    Nov 1, 2019, 00:00

  • PCN190 COST–BENEFIT ANALYSIS OF INTERVENTIONS MADE BY PHARMACISTS IN CHEMOTHERAPY PREPARATION OF A REFERRAL HOSPITAL IN IRAN

    Nov 1, 2019, 00:00

  • PSU20 APPLY PRINCIPLES AND GOOD PRACTICE OF BUDGET IMPACT ANALYSIS IN MODEL FRAMEWORK DEVELOPMENT FOR SURGICAL DEVICE

    Nov 1, 2019, 00:00

  • PCN463 EUROQOL-5D ASSESSED HEALTH-RELATED QUALITY OF LIFE IN CANCER PATIENTS VS. GENERAL POPULATION IN BULGARIA

    Nov 1, 2019, 00:00

  • PRO144 HEALTH-RELATED QUALITY OF LIFE AND PATIENT REPORTED OUTCOMES MEASURES IN IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PSY9 PREFERENCE WEIGHTS FOR QUALITY-ADJUSTED LIFE-YEARS ESTIMATION FOR TREATMENTS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN392 UTILISATION OF REAL-WORLD EVIDENCE IN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SUBMISSIONS OF THE TOP 20 ONCOLOGY DRUGS

    Nov 1, 2019, 00:00

  • PGI7 THE CLINICAL IMPACT OF THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE ─ A CRITICAL LITERATURE REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PIN68 THE COST-EFFECTIVENESS OF HEPATITIS C VIRUS SCREENING AND TREATMENT STRATEGIES AMONG RECENTLY ARRIVED MIGRANTS FOR THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PMD18 A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF C-REACTIVE PROTEIN POINT-OF-CARE TESTING TO GUIDE ANTIBIOTIC PRESCRIBING FOR RESPIRATORY TRACT INFECTIONS IN PRIMARY CARE SETTINGS IN IRELAND

    Nov 1, 2019, 00:00

  • PSS3 INDUCTION COST PER RESPONDER OF BRODALUMAB COMPARED WITH OTHER BIOLOGICS APPROVED FOR PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN CANADA

    Nov 1, 2019, 00:00

  • PBI73 ASSESSMENT OF THE FUTURE IMPACT OF BIOSIMILARS AND GENERICS FOR ULCERATIVE COLITIS IN THE US EUROPE

    Nov 1, 2019, 00:00

  • PIH48 EVALUATING COVERAGE EXPANSION FOR NON-INVASIVE PRENATAL TESTING THROUGH A PERFORMANCE-BASED RISK SHARING AGREEMENT

    Nov 1, 2019, 00:00

  • PIN23 TREATING PATIENTS WITH DAAS ALLOWED TO SAVE 1 BILLION EUROS IN FRANCE - A BUDGET IMPACT MODEL FROM 2014 TO 2018

    Nov 1, 2019, 00:00

  • PMU31 EARLY COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS MONITORING OF LUNG-AERATION WITH ELECTRICAL IMPEDANCE TOMOGRAPHY IN PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME

    Nov 1, 2019, 00:00

  • PDG61 CANCER DRUGS SHORTAGES IN ROMANIA: MAGNITUDE, CAUSES AND SOLUTIONS

    Nov 1, 2019, 00:00

  • PCV68 ECONOMIC BURDEN OF ATHEROTROMBOTIC DISEASE IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00

  • PCN271 HODGKIN LYMPHOMA IN EUROPEAN COUNTRIES: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN74 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF-MUTATED METASTATIC MELANOMA PATIENTS IN REAL LIFE IN FRANCE

    Nov 1, 2019, 00:00

  • PGI20 MULTIMATRIX VERSUS TIME-DEPENDENT DELIVERY OF MESALAZINE FOR ULCERATIVE COLITIS THERAPY IN KAZAKHSTAN: A HEALTH ECONOMIC EVALUATION

    Nov 1, 2019, 00:00

  • PMH5 PATIENTS MAY BE CONCERNED WITH THE CONSEQUENCES OF THEIR ANSWERS WHEN REPORTING ON SYMPTOMS OF DEPRESSION

    Nov 1, 2019, 00:00

  • PRO126 A COMPOSITE PROGNOSTIC SCORE FOR TIME TO LOSS OF WALKING ABILITY IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

    Nov 1, 2019, 00:00

  • PCV148 ESTIMATE OF THE IMPACT AND COSTS OF CEREBROVASCULAR DISEASE FROM A HEALTH PLAN IN BRAZIL: REAL WORLD SCENARIO STUDY

    Nov 1, 2019, 00:00

  • PGI60 IDENTIFYING PROGRESSING PATIENTS IN AN ARTIFICIAL INTELLIGENCE (AI) BASED COHORT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • PIN26 ESTIMATING THE INVASIVE CANDIDIASIS COST-OF-CARE IN INTENSIVE CARE UNITS IN GREECE (HELICAS)

    Nov 1, 2019, 00:00

  • Mental Health - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PMD7 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A BELGIAN HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRO81 EVOLVING COMMERCIALISATION OPPORTUNITIES IN RARE DISEASES OUTSIDE EUROPE

    Nov 1, 2019, 00:00

  • PNS408 HOW IS THE ENGLISH NHS PRESCRIPTION DRUGS BUDGET SPENT

    Nov 1, 2019, 00:00

  • PMD22 COST-EFFECTIVENESS ANALYSIS OF SUCROSE OCTASULFATE (URGOSTART) DRESSING IN THE TREATMENT OF DIABETIC FOOT AND VENOUS LEG ULCERS

    Nov 1, 2019, 00:00

  • PIN7 ANALYSIS OF THE EFFECTIVENESS OF ENHANCE ADHERENCE COUNSELLING (EAC) ON VIRALLY UNSUPPRESSED HIV PATIENTS IN ST CHARLES BORROMEO HOSPITAL, ONITSHA METROPOLIS, ANAMBRA STATE, NIGERIA.

    Nov 1, 2019, 00:00

  • PNS180 MONITORING OF DRG-BASED PAYMENT FOR IN-PATIENT AND DAY CARE IN RUSSIAN HOSPITALS IN 2016-2018

    Nov 1, 2019, 00:00

  • PCN420 NEW METHODOLOGIES IN PARAMETRIC NETWORK META-ANALYSIS: ACCOUNTING FOR POPULATION AGE DIFFERENCES BETWEEN TRIALS

    Nov 1, 2019, 00:00

  • PDG13 CAN THE PURCHASING PERFORMANCE OF HEALTHCARE INSTITUTIONS BE ASSESSED VIA THE DATA DECLARED FOR REIMBURSEMENT?

    Nov 1, 2019, 00:00

  • PRO159 PAEDIATRIC AND ADULT GHD TESTS FOR DIAGNOSIS IN EUROPE

    Nov 1, 2019, 00:00

  • Copyright/Subscription

    Nov 1, 2019, 00:00

  • PND100 REFINEMENT OF THE TREATMENT PREFERENCE QUESTIONNAIRE IN ADULTS WITH PARKINSON'S DISEASE AND OFF-EPISODES

    Nov 1, 2019, 00:00

  • PUK19 COST CONSEQUENCE ANALYSIS OF A REMOTE MONITORING PROGRAM FOR AUTOMATED PERITONEAL DYALISIS IN US

    Nov 1, 2019, 00:00

  • PCN504 REAL-WORLD PROGRESSION-FREE AND OVERALL SURVIVAL OF METASTATIC BREAST CANCER PATIENTS: ANALYSIS OF A NEW GERMAN EMR DATASET

    Nov 1, 2019, 00:00

  • PDG20 GLOBAL COMPARISON AND META-ANALYSIS OF INCREMENTAL COST-EFFECTIVENESS (ICER) FOR NEW CANCER DRUGS

    Nov 1, 2019, 00:00

  • PND34 ECONOMIC BURDEN OF PARKINSON'S DISEASE (PD) IN U.S.: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDG57 DRUG PRICING PREDICTABILITY IN FRANCE: WHICH MANAGED ENTRY AGREEMENT SUITS THE BEST?

    Nov 1, 2019, 00:00

  • PSS12 COMPARATIVE ANALYSIS OF GLAUCOMA DRUG CONSUMPTION IN UKRAINE, ESTONIA, AND NORWAY

    Nov 1, 2019, 00:00

  • PRO60 PREVALENCE OF SANFILIPPO SYNDROME AND SUB-TYPES IN MAJOR GEOGRAPHICAL REGIONS

    Nov 1, 2019, 00:00

  • PSY46 WORK PRODUCTIVITY LOSS IN PATIENTS WITH INFLAMMATORY ARTHRITIS

    Nov 1, 2019, 00:00

  • PDB30 THE INDIRECT COSTS OF DIABETES MELLITUS IN THE SLOVAK REPUBLIC

    Nov 1, 2019, 00:00

  • PNS171 GEOGRAPHICAL INEQUALITIES OF GENERAL PRACTITIONER CARE IN HUNGARY BETWEEN 2009-2016

    Nov 1, 2019, 00:00

  • PCN134 SOCIO-ECONOMIC COSTS OF BREAST CANCER: AN ITALIAN ANALYSIS

    Nov 1, 2019, 00:00

  • PDB103 HUMANISTIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS287 PATIENT-CENTRICITY FOR PHARMACEUTICAL COMPANIES: NEW MODELS IN THE ERA OF CONNECTED HEALTH

    Nov 1, 2019, 00:00

  • PCN34 CLINICAL AND HUMANISTIC BURDEN AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PRO33 IMPACT ON PRODUCTIVITY ASSOCIATED WITH THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR HEMOPHILIA A WITH INHIBITORS IN COLOMBIA

    Nov 1, 2019, 00:00

  • PUK13 COST-EFFECTIVENESS OF INTRODUCING A DIETARY INTERVENTION FOR RENAL TRANSPLANT RECIPIENTS

    Nov 1, 2019, 00:00

  • PSY6 ABSENTEEISM IN ADULT PATIENTS WITH MODERATE-TO-SEVERE TREATED ATOPIC DERMATITIS IN PORTUGAL: AN ECONOMETRIC ANALYSIS

    Nov 1, 2019, 00:00

  • PNS144 HOW THE RESULTS OF THE AMNOG EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY HAVE DEVELOPED OVER TIME

    Nov 1, 2019, 00:00

  • PNS60 CAN WE APPLY NICE COST-EFFECTIVENESS TO FRENCH EFFICIENCY OPTIONS: A COMPARISON OF SEVEN NICE AND HAS BASECASE COST-EFFECTIVENESS SCENARIOS

    Nov 1, 2019, 00:00

  • PIN96 EPIDEMIOLOGICAL AND ECONOMIC IMPACTS OF POTENTIAL HCV SCREENING STRATEGIES FOR THE NEXT 5 YEARS IN FRANCE

    Nov 1, 2019, 00:00

  • PMU19 RARE DISEASES AND THE COST FOR SOCIAL SECURITY SYSTEM: ESTIMATING THE SOCIO-ECONOMIC BURDEN IN ITALY

    Nov 1, 2019, 00:00

  • PMH49 PERSONALIZED HEALTHCARE EPISODE IDENTIFICATION IN SCHIZOPHRENIA SPECTRUM DISORDER USING HEALTHCARE CONSUMPTION TRAJECTORIES

    Nov 1, 2019, 00:00

  • PNS400 TREND IN STUDIES ON PATIENT REPORTED OUTCOMES

    Nov 1, 2019, 00:00

  • PNS188 ANALYSIS OF MARKET ACCESS AGREEMENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PIH59 KNOWLEDGE OF HUMAN PAPILLOMAVIRUSAMONG WOMEN LIVINGIN SOMOGY AND BARANYA COUNTIES, HUNGARY

    Nov 1, 2019, 00:00

  • PCN40 A SYSTEMATIC LITERATURE REVIEW (SLR) TO SUPPORT NETWORK META-ANALYSES (NMA) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FOLLOWING PD-1/L1 INHIBITORS

    Nov 1, 2019, 00:00

  • PSY52 PATIENT-REPORTED OUTCOME MEASURES IN ATOPIC DERMATITIS AND CHRONIC HAND ECZEMA IN ADULTS

    Nov 1, 2019, 00:00

  • PRO31 MEDICAL INNOVATION ASSESSMENT AND ECONOMIC BURDEN OF DISEASES ON THE EXAMPLE OF RARE AND COMMON DISEASES IN POLAND

    Nov 1, 2019, 00:00

  • Multiple Diseases - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PDG51 OPTIMIZING CHINA BMI FUNDS THROUGH DRUG VOLUME-BASED PROCUREMENT: UNDERSTANDING THE RESULT, IMPACT AND CHALLENGES

    Nov 1, 2019, 00:00

  • PCV128 DEVELOPING AN EQ-5D-5L VALUE SET USING HEART DISEASE PATIENT'S PREFERENCES

    Nov 1, 2019, 00:00

  • PMU16 SOCIETAL DISEASE SEVERITY PREFERENCES WHEN VALUING AND PRIORITIZING HEALTHCARE INTERVENTIONS.

    Nov 1, 2019, 00:00

  • PNS303 BAYESIAN ESTIMATION OF THE TRANSITION PROBABILITY MATRIX IN MARKOV MODELLING WITH INFORMATIVE PRIOR: AN EXAMPLE FROM THE ANALYSIS OF THE TREATMENT OF PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH CARIPRAZINE

    Nov 1, 2019, 00:00

  • PCN83 COST-UTILITY ANALYIS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES IN HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • PND85 EFFICACY AND SAFETY OF ABOBOTULINUMTOXINA IN ADULTS WITH UPPER LIMB SPASTICITY AFTER STROKE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCV138 CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE PERIPHERAL ARTERY DISEASE QUALITY OF LIFE (PADQOL) QUESTIONNAIRE INTO HUNGARIAN: PILOTING RESULTS

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • IN3 THE HEALTH SYSTEM BURDEN OF SELECTED VACCINE-PREVENTABLE ILLNESSES ON SECONDARY CARE IN ENGLAND: A FIVE-YEAR STUDY USING AN ADMINISTRATIVE HEALTHCARE DATASET

    Nov 1, 2019, 00:00

  • PCN523 INCIDENCE AND COST OF NON-CERVICAL HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED CANCER IN KOREA

    Nov 1, 2019, 00:00

  • PMH8 PSYCHOLOGICAL ASPECTS OF GENETIC COUNSELING IN RARE GENETIC CNS DISORDERS - SHOULD REGULATORS BE MORE INVOLVED?

    Nov 1, 2019, 00:00

  • PCN476 THE PATIENT JOURNEY WITH METASTATIC PROSTATE CANCER: A PILOT QUALITATIVE STUDY FROM GREECE

    Nov 1, 2019, 00:00

  • PDB27 ONCE-WEEKLY SEMAGLUTIDE COMPARED TO OTHER TWO GLP1-RAS AVAILABLE IN THE PUBLIC HEALTHCARE SYSTEM IN THE KINGDOM OF SAUDI ARABIA: A RELATIVE COST OF CONTROL ANALYSIS

    Nov 1, 2019, 00:00

  • PRO95 FROM DRUG ACCESS TO VALUE BASED HEALTHCARE: INTEGRATED CARE PATHWAYS FOR HEMOPHILIA IN ITALY

    Nov 1, 2019, 00:00

  • PCN329 TREATMENT PATTERNS IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PATIENTS IN SPAIN.

    Nov 1, 2019, 00:00

  • PND110 SYMPTOM SEVERITY IN MULTIPLE SCLEROSIS FROM THE PATIENT'S PERSPECTIVE: REVISITING THE PSYCHOMETRIC PROPERTIES OF THE SYMPTOMSCREEN QUESTIONNAIRE (PERCEPTIONS-MS STUDY)

    Nov 1, 2019, 00:00

  • PCN389 MATURE VERSUS REGISTRATION STUDIES OF IMMUNO-ONCOLOGY AGENTS: DOES VALUE IMPROVE WITH TIME?

    Nov 1, 2019, 00:00

  • PCV133 HETEROGENEITY IN PREFERENCES FOR ANTI-COAGULANT USE IN ATRIAL FIBRILLATION: A LATENT CLASS ANALYSIS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PCN483 CONFIRMING THE PSYCHOMETRIC PERFORMANCE OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY–MELANOMA (FACT-M) QUESTIONNAIRE IN PATIENTS WITH MERKEL CELL CARCINOMA (MCC)

    Nov 1, 2019, 00:00

  • PIN9 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PIN31 COST PER CYTOMEGALOVIRUS-ASSOCIATED DEATH AVERTED OF GANCICLOVIR AND VALGANCICLOVIR USE FOR PRE-EMPTIVE AND TREATMENT STRATEGIES IN ALLOGENEIC POSTTRANSPLANT RECIPIENTS

    Nov 1, 2019, 00:00

  • PMS39 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE SHOULDER AND UPPER ARM IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PCN39 TREATMENT PATTERNS, MINIMAL RESIDUAL DISEASE (MRD) TESTING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PATIENT CHART REVIEW IN BELGIUM, GREECE AND SWITZERLAND

    Nov 1, 2019, 00:00

  • PCN289 READINESS OF HEALTH SYSTEMS FOR THE INTRODUCTION OF TUMOUR-AGNOSTIC TREATMENT

    Nov 1, 2019, 00:00

  • PSU38 COST-EFFECTIVE ANALYSIS OF THREE METHODS OF SURGICAL-SITE INFECTION SURVEILLANCE: LESS IS MORE

    Nov 1, 2019, 00:00

  • CE4 COMPARISON OF NETWORK META-ANALYSIS (NMA) USING THE BAYESIAN AND FREQUENTIST APPROACH: CONCRETE EXAMPLE ON THE BASIS OF A PUBLISHED NMA IN RELAPSING REMITTING MULTIPLE SCLEROSIS AND PLAQUE PSORIASIS

    Nov 1, 2019, 00:00

  • PNS70 THE EFFECT OF OUT-OF-POCKET HEALTHCARE PAYMENT ON THE FINANCES OF NIGERIAN FAMILIES

    Nov 1, 2019, 00:00

  • PMS18 THE EXAMINATION AND DEVELOPMENT OF TRUNK STABILITY IN HIGH SCHOOL STUDENTS

    Nov 1, 2019, 00:00

  • PCV52 TRANSFERABILITY OF UK-BASED COST-EFFECTIVENESS MODEL TO HUNGARY, SWEDEN AND GERMANY: THE CASE OF MECHANICAL THROMBECTOMY BEYOND SIX HOURS FOLLOWING ADVANCED-IMAGING (VERSUS MECHANICAL THROMBECTOMY WITHIN SIX HOURS FOLLOWING CT+CTA) IN ...

    Nov 1, 2019, 00:00

  • PNS15 COVARIATE ADJUSTMENT IN INDIRECT TREATMENT COMPARISON (ITC): HOW TO BLEND THE USEFUL WITH THE AGREEABLE

    Nov 1, 2019, 00:00

  • PDG70 KNOWLEDGE, ATTITUDES AND PRACTICES OF MOROCCAN COMMUNITY PHARMACISTS TOWARDS THE THIRD-PARTY PAYER SYSTEM

    Nov 1, 2019, 00:00

  • PUK4 WHERE IS HYPERKALEMIA DIAGNOSED AND DOES IT MATTER? RESULTS FROM A LARGE EMR NETWORK IN THE US

    Nov 1, 2019, 00:00

  • PGI11 A BUDGET IMPACT MODEL FOR MEDICATION REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE PATIENTS TREATED WITH LAPAROSCOPIC NISSEN FUNDOPLICATION OR MAGNETIC SPHINCTER AUGMENTATION: AN ITALIAN PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU21 COST-UTILITY ANALYSES OF INTERVENTIONS FOR INFORMAL CAREGIVERS: A SYSTEMATIC AND CRITICAL REVIEW

    Nov 1, 2019, 00:00

  • PNS284 IS THERE A NEED FOR REAL WORLD EVIDENCE (RWE) IN HEALTH TECHNOLOGY ASSESSMENTS OF RARE DISEASES AND ONCOLOGY TREATMENTS?

    Nov 1, 2019, 00:00

  • PSY48 DO CLINICAL AND DEMOGRAPHIC CHARACTERISTICS AFFECT PATIENT PREFERENCE HETEROGENEITY FOR PSORIASIS TREATMENTS? RESULTS FROM A DISCRETE-CHOICE EXPERIMENT IN A MULTICOUNTRY STUDY

    Nov 1, 2019, 00:00

  • PBI80 VARIATIONS IN TREATMENT PATTERNS OF PSORIASIS PATIENTS CURRENTLY EXPERIENCING 1ST LINE BIOLOGIC THERAPY IN EUROPE

    Nov 1, 2019, 00:00

  • PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN

    Nov 1, 2019, 00:00

  • PNS409 ANALYSIS OF EPIDEMIOLOGY AND PHARMACOUTILIZATION ON PATIENTS AFFECTED BY OPHTHALMIC DISEASES WITH INDICATIONS FOR INTRAVITREAL TREATMENTS IN A NORTHERN ITALIAN REGION

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PGI35 THE CLINICAL AND ECONOMIC IMPACT OF TDM (THERAPEUTIC DRUG MONITORING) ON CROHN DISEASE MANAGEMENT IN ITALY

    Nov 1, 2019, 00:00

  • PCN418 ASSESSMENT OF STUDIES EVALUATING INCREMENTAL COSTS, EFFECTIVENESS OR COST-EFFECTIVENESS OF SYSTEMIC THERAPIES IN BREAST CANCER BASED ON CLAIMS DATA: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN188 THE COST-EFFECTIVENESS OF PARENTERAL NUTRITION IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN520 CLINICAL AND ECONOMIC EVALUATIONS OF MULTIPLE MYELOMA PATIENTS

    Nov 1, 2019, 00:00

  • PCN274 CLINICAL FACTORS ASSOCIATED WITH ADHERENCE TO THE SECONDARY SCREENING FOR COLORECTAL CANCER ACCORDING TO AGE IN KOREAN NATIONAL CANCER SCREENING PROGRAM

    Nov 1, 2019, 00:00

  • PCN343 INVESTIGATING EUROPEAN HTA AND PRICING FOR HISTOLOGY-AGNOSTIC TREATMENTS

    Nov 1, 2019, 00:00

  • PNS241 EXPERIENCE AND IMPACT OF NICE SCIENTIFIC ADVICE: 10 YEARS ON

    Nov 1, 2019, 00:00

  • PMU47 ORPHAN DRUG DESIGNATION: NO IMPACT ON PR PROCESS TIMING IN ITALY

    Nov 1, 2019, 00:00

  • PRO116 UNDERSTANDING THE ROLE OF REAL-WORLD EVIDENCE IN HEALTH TECHNOLOGY ASSESSMENT FOR ORPHAN DRUGS

    Nov 1, 2019, 00:00

  • PBI43 THE IMPACT OF BIOSIMILAR PRICE CONTAGION ON NEW INNOVATION IN INFLAMMATORY DISEASES

    Nov 1, 2019, 00:00

  • PSY21 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN97 DIRECT COSTS ASSOCIATED WITH NEUTROPENIA AND FEBRILE NEUTROPENIA AS ADVERSE EVENTS OF CHEMOTHERAPY IN SERBIAN CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PNS114 IMPROVING THE TRANSPARENCY OF MARKETING AUTHORISATION DECISIONS: TOWARDS A FRAMEWORK FOR MANAGING UNCERTAINTIES

    Nov 1, 2019, 00:00

  • PCN508 A COMPARISON OF PATIENT CHARACTERISTICS TREATED WITH NIVOLUMAB FOR RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN GERMANY AND THE USA

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • Surgery - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS22 USING TWITTER TO HARVEST DATA FROM SCIENTIFIC CONFERENCES:A PROOF OF CONCEPT OF A NEW APPROACH TO RETRIEVE CLINICAL TRIAL RESULTS

    Nov 1, 2019, 00:00

  • Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications

    Nov 1, 2019, 00:00

  • PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY

    Nov 1, 2019, 00:00

  • PIT4 PATIENT CHARACTERISTICS AND HEALTHCARE UTILIZATION FOLLOWING COMMINUTED GUSTILO-ANDERSON TYPE III FRACTURES

    Nov 1, 2019, 00:00

  • ON3 HOSPITAL COSTS BEFORE, DURING, AND AFTER DIAGNOSIS OF FIVE CANCER FORMS IN DENMARK DURING 2014

    Nov 1, 2019, 00:00

  • PND23 HEALTHCARE EXPENDITURES ASSOCIATED WITH ADHERENCE TO ANTIDEPRESSANT MEDICATION MANAGEMENT MEASURES DURING ACUTE AND CONTINUATION PHASES OF DEPRESSION TREATMENT AMONG OLDER ADULTS WITH DEMENTIA AND MAJOR DEPRESSIVE DISORDER

    Nov 1, 2019, 00:00

  • PDG43 ARE PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS AGREEMENTS ESSENTIAL FOR NICE TO RECOMMEND ACCESS? A COMPARISON OF ONCOLOGY AND NON-ONCOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PCN314 POPULATION BASED STUDY OF BASELINE BONE DENSITY SCREENING IN PROSTATE CANCER PATIENTS TREATED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY

    Nov 1, 2019, 00:00

  • PCN362 DO ANTICANCER DRUGS ENTERING THE FRENCH MARKET PROVIDE SIGNIFICANT EVIDENCE OF THEIR CLINICAL EFFICACY?

    Nov 1, 2019, 00:00

  • Individual's Health - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PNS245 SNAPSHOT OF EARLY ACCESS PROGRAMMES IN PORTUGAL: A NEW ACCESS HURDLE?

    Nov 1, 2019, 00:00

  • Medical Devices - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN163 SEQUENTIAL TREATMENT REGIMENS FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A COST-EFFECTIVENESS ANALYSIS INCLUDING EXPERIENCE FROM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PCN302 NEW DRG-BASED REIMBURSEMENT OF RADIATION THERAPY AT RUSSIAN HOSPITALS

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PNS362 EQ-5D-5L DATA FOR BULGARIAN POPULATION

    Nov 1, 2019, 00:00

  • PNS107 PHARMACISTS KNOWLEDGE OF PROJECT MANAGEMENT PROPOSAL OR CHART

    Nov 1, 2019, 00:00

  • PND6 CLINICALLY RELEVANT REDUCTION OF MIGRAINE SYMPTOMS BY FREMANEZUMAB IN PATIENTS WITH UP TO ONE PREVENTIVE MIGRAINE PROPHYLAXIS TREATMENT IN THE PAST

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PIH50 MODERN APPROACH TO CREATION OF DONOR BREAST MILK BANKS IN UKRAINE

    Nov 1, 2019, 00:00

  • PDB29 COST-EFFECTIVENESS ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCN341 HOW INFLUENTIAL IS BUDGET IMPACT IN DETERMINING PRICING FOR ONCOLOGY PRODUCTS?: A REGRESSION ANALYSIS

    Nov 1, 2019, 00:00

  • PCN398 THE IMPORTANCE OF DIFFERENT ENDPOINTS IN ONCOLOGY-RELATED HEALTH TECHNOLOGY ASSESSMENTS: RESULTS OF A REVIEW OF DECISIONS IN GERMANY

    Nov 1, 2019, 00:00

  • PMD50 COMPARING THE ABILITY OF TWO INNOVATIVE OSTOMY BAGS TO PREVENT BALLOONING IN A REAL-LIFE SETTING

    Nov 1, 2019, 00:00

  • Clinical Outcomes Assessment Studies

    Nov 1, 2019, 00:00

  • PNS369 RECOMMENDATIONS FOR CONDUCTING COGNITIVE INTERVIEWS REMOTELY TO DEVELOP CLINICAL OUTCOME ASSESSMENTS

    Nov 1, 2019, 00:00

  • PCN429 THE GENERATION OF SYNTHETIC CLINICAL TRIAL DATA

    Nov 1, 2019, 00:00

  • PCN130 COST OF ILLNESS ANALYSIS: DRUG THERAPY OF PATIENTS WITH MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS IN MOSCOW

    Nov 1, 2019, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55 (current)
  • 56
  • 57
  • 58
  • 59
  • 60
  • »